1138-79-0

Basic information

• Product Name: 2-chloro-N-(2-chloroethyl)-N-(2-phenylethyl)ethanamine
• Synonyms: 2-Chloro-N-(2-chloroethyl)-N-(2-phenylethyl)ethanamine; benzeneethanamine, N,N-bis(2-chloroethyl)-
• CAS NO: 1138-79-0
• Molecular Formula: C₁₂H₁₇Cl₂N
• Molecular Weight: 246.1761
• Mol File: 1138-79-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 278.5°C at 760 mmHg
• Flash Point: 122.2°C
• Density: 1.127g/cm³
• Vapor Pressure: 0.00424mmHg at 25°C
• Refractive Index: 1.533
• CAS DataBase Reference: 2-chloro-N-(2-chloroethyl)-N-(2-phenylethyl)ethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-N-(2-chloroethyl)-N-(2-phenylethyl)ethanamine(1138-79-0)
• EPA Substance Registry System: 2-chloro-N-(2-chloroethyl)-N-(2-phenylethyl)ethanamine(1138-79-0)

Safety Data

• Hazardous Substances Data: 1138-79-0(Hazardous Substances Data)

Upstream product

• 4142-04-5 2-[(2-Hydroxy-ethyl)-(2-phenyl-ethyl)-amino]-ethanol 

Downstream Products

• 212771-06-7 4-(4-methoxy-benzenesulfonyl)-1-(2-phenyl-ethyl)-piperidine-4-carboxylic acid ethyl ester 

Relevant articles and documents

Unique spirocyclopiperazinium salt III: Further investigation of monospirocyclopiperazinium (MSPZ) salts as potential analgesics

Two novel classes of monospirocyclopiperazinium salts were designed, synthesized, and evaluated for their in vivo analgesic activities. Some interesting structure-activity relationships are revealed: (1) Spirocyclopiperazinium moiety is favorable to improve the analgesic activity; (2) The size and conformation of spirocyclopiperazinium moiety significantly affects the analgesic activity; (3) Phenylethyl group of 3d is a crucial pharmacophore. Among the compounds synthesized, 3d exhibited the most potent activity with low toxicity. Further antinociceptive mechanism studies of 3d showed that these compounds will be a new kind of analgesics.

N-hydroxy-2-(Alkyl,Aryl or Heteroaryl sulfanyl, sulfinyl or sulfonyl) 3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors

Matrix metalloproteinases (MMps) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-α converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-α from membrane bound TNF-α precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. The present invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF-α converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection. The compounds of this invention are represented by the formula where R1, R2, R3and R4are described herein.